Filippo Pietrantonio, MD; Federica Morano, MD; Salvatore Corallo, MD; et al.
open access
JAMA Oncol. 2019;5(9):1268-1275. doi:10.1001/jamaoncol.2019.1467
This open-label, phase 2 randomized clinical trial assesses whether maintenance therapy with single-agent panitumumab was noninferior to panitumumab plus combined fluorouracil and leucovorin calcium among patients with RAS wild-type metastatic colorectal cancer.
-
Editorial
Panitumumab Alone for Maintenance Treatment in Advanced Colorectal Cancer
Gayathri Anandappa, MBBS, MPhil, MRCP; David Cunningham, MD, FRCP, FMedSci
Willemijn S. M. E. Theelen, MD; Heike M. U. Peulen, MD, PhD; Ferry Lalezari, MD; et al.
JAMA Oncol. 2019;5(9):1276-1282. doi:10.1001/jamaoncol.2019.1478
This phase 2 randomized clinical trial assesses whether pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone enhances tumor response in patients with metastatic non–small cell lung cancer.
-
Invited Commentary
Radiotherapy and Immunotherapy—Shining Further Together
Joshua Walker, MD, PhD; Billy W. Loo Jr, MD, PhD
Joshua M. Bauml, MD; Rosemarie Mick, MS; Christine Ciunci, MD, MSCE; et al.
JAMA Oncol. 2019;5(9):1283-1290. doi:10.1001/jamaoncol.2019.1449
This phase 2 single-arm study evaluates outcomes following pembrolizumab treatment after locally ablative therapy in patients with oligometastatic non–small cell lung cancer.
-
Invited Commentary
Radiotherapy and Immunotherapy—Shining Further Together
Joshua Walker, MD, PhD; Billy W. Loo Jr, MD, PhD
Ola Landgren, MD, PhD; Jonathan N. Hofmann, PhD, MPH; Charlene M. McShane, PhD; et al.
JAMA Oncol. 2019;5(9):1293-1301. doi:10.1001/jamaoncol.2019.1568
This cohort study investigates the association of prediagnostic serum immune markers with the subsequent diagnosis of stable monoclonal gammopathy of undetermined significance vs progression to multiple myeloma.
-
Invited Commentary
Monoclonal Gammopathy May Be of Unpredictable Significance
Nikhil C. Munshi, MD; Sundar Jagannath; Herve Avet-Loiseau
Nancy Y. Yu, PhD; Adina Iftimi, PhD; Christina Yau, PhD; et al.
JAMA Oncol. 2019;5(9):1304-1309. doi:10.1001/jamaoncol.2019.1856
This secondary analysis of the Stockholm Tamoxifen (STO-3) clinical trial, which was conducted from 1976 to 1990, assessed the long-term survival associated with tamoxifen therapy in postmenopausal patients with luminal A or B breast cancer tumor subtypes.
Audrey Simonaggio, MD; Jean Marie Michot, MD; Anne Laure Voisin, MD; et al.
JAMA Oncol. 2019;5(9):1310-1317. doi:10.1001/jamaoncol.2019.1022
This cohort study evaluates the feasibility, risks, and advantages of resuming immune checkpoint inhibitor therapy in patients with cancer who experienced severe immune-related adverse events.
Melinda C. Aldrich, PhD; Sarah F. Mercaldo, PhD; Kim L. Sandler, MD; et al.
has audio
JAMA Oncol. 2019;5(9):1318-1324. doi:10.1001/jamaoncol.2019.1402
This cohort study uses data from the Southern Community Cohort Study to evaluate whether race-specific adjustment of pack-year criteria in the US Preventive Services Task Force (USPSTF) lung cancer screening guidelines is associated with more equitable screening for African American smokers at high risk for lung cancer.
-
Audio Interview:
Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers
Maegan E. Roberts, MS; John Michael O. Ranola, PhD; Megan L. Marshall, MS; et al.
JAMA Oncol. 2019;5(9):1325-1331. doi:10.1001/jamaoncol.2019.1208
This review of data from 75 families with a CDH1 pathologic variant compares estimates of the lifetime risk of gastric cancer in the families found to have a CDH1 pathologic variant through clinical ascertainment with those ascertained through multigene panel testing.
Thomas S. Uldrick, MD, MS; Priscila H. Gonçalves, MD; Maher Abdul-Hay, MD; et al.
has multimedia
JAMA Oncol. 2019;5(9):1332-1339. doi:10.1001/jamaoncol.2019.2244
This open-label, nonrandomized, phase 1 study assesses the safety of pembrolizumab in patients with HIV and advanced cancer.
Farhad Islami, MD, PhD; Kimberly D. Miller, MPH; Rebecca L. Siegel, MPH; et al.
online only
JAMA Oncol. 2019;5(9):e191460. doi:10.1001/jamaoncol.2019.1460
This population-based study estimates earnings lost owing to death from cancer in the United States nationally and by state.
Anna E. Coghill, PhD, MPH; Gita Suneja, MD; Anne F. Rositch, PhD; et al.
online only
JAMA Oncol. 2019;5(9):e191742. doi:10.1001/jamaoncol.2019.1742
This database study compared cancer-specific mortality in HIV-infected vs HIV-uninfected elderly patients after adjusting data for receipt of specific cancer treatments.